Worldwide Drug Delivery Devices Industry to 2026 - Rising Adoption of Self-injectable Devices Presents Opportunities


Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Drug Delivery Devices Market Research Report by Route of Administration, Vehicles, Application, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Drug Delivery Devices Market size was estimated at USD 1,717.41 million in 2020, is expected to reach USD 1,853.26 million in 2021, and projected to grow at a CAGR of 8.24% reaching USD 2,763.15 million by 2026.

Market Statistics

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage

This research report categorizes the Drug Delivery Devices to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Route of Administration, the market was studied across Inhalation, Injectable, Nasal, Ocular, Oral, Topical, and Transdermal.
  • Based on Vehicles, the market was studied across Dendrimer, Hydrogel, Liposome, Mesoporous Material, Micelle, Nanoparticle, Niosomes, and Scaffold.
  • Based on Application, the market was studied across Autoimmune Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Infectious Diseases, Oncology, and Respiratory Diseases.
  • Based on End-user, the market was studied across Ambulatory Surgery Centers/Clinics, Diagnostic Centers, Home Care Settings, and Hospitals.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Drug Delivery Devices Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Drug Delivery Devices Market, including 3M Company, Abbott Laboratories, Antares Pharma, Inc., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eisai Co., Ltd, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline PLC, Insulet Corporation, Johnson & Johnson Services Inc., Koninklijke Philips N.V., Merck & Co., Inc., OraSure Technologies, Inc., Panacea Acquisition Corp., Pfizer Inc., Sanofi SA, Smith Medical, Sulzer Ltd, and West Pharmaceutical Services, Inc.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Drug Delivery Devices Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Drug Delivery Devices Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Drug Delivery Devices Market?
4. What is the competitive strategic window for opportunities in the Global Drug Delivery Devices Market?
5. What are the technology trends and regulatory frameworks in the Global Drug Delivery Devices Market?
6. What is the market share of the leading vendors in the Global Drug Delivery Devices Market?
7. What modes and strategic moves are considered suitable for entering the Global Drug Delivery Devices Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing prevalence of chronic diseases globally resulting
5.2.2. Rise in the consumption of drugs and therapeutic pharmaceuticals
5.3. Restraints
5.3.1. Increase in complications and expertise required in delivering therapeutics and drugs
5.4. Opportunities
5.4.1. Favorable government policies regarding health care infrastructure
5.4.2. Rising adoption of self-injectable devices
5.5. Challenges
5.5.1. Increasing cost of high-end products

6. Drug Delivery Devices Market, by Route of Administration
6.1. Introduction
6.2. Inhalation
6.3. Injectable
6.4. Nasal
6.5. Ocular
6.6. Oral
6.7. Topical
6.8. Transdermal

7. Drug Delivery Devices Market, by Vehicles
7.1. Introduction
7.2. Dendrimer
7.3. Hydrogel
7.4. Liposome
7.5. Mesoporous Material
7.6. Micelle
7.7. Nanoparticle
7.8. Niosomes
7.9. Scaffold

8. Drug Delivery Devices Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cardiovascular Diseases
8.4. Central Nervous System Disorders
8.5. Diabetes
8.6. Infectious Diseases
8.7. Oncology
8.8. Respiratory Diseases

9. Drug Delivery Devices Market, by End-user
9.1. Introduction
9.2. Ambulatory Surgery Centers/Clinics
9.3. Diagnostic Centers
9.4. Home Care Settings
9.5. Hospitals

10. Americas Drug Delivery Devices Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Drug Delivery Devices Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand

12. Europe, Middle East & Africa Drug Delivery Devices Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, by Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. 3M Company
14.2. Abbott Laboratories
14.3. Antares Pharma, Inc.
14.4. B. Braun Melsungen AG
14.5. Baxter International Inc.
14.6. Becton, Dickinson and Company
14.7. Eisai Co., Ltd.
14.8. Enable Injections, Inc.
14.9. Gerresheimer AG
14.10. GlaxoSmithKline PLC
14.11. Insulet Corporation
14.12. Johnson & Johnson Services Inc.
14.13. Koninklijke Philips N.V.
14.14. Merck & Co., Inc.
14.15. OraSure Technologies, Inc.
14.16. Panacea Acquisition Corp.
14.17. Pfizer Inc.
14.18. Sanofi SA
14.19. Smith Medical
14.20. Sulzer Ltd.
14.21. West Pharmaceutical Services, Inc.

15. Appendix

For more information about this report visit


Contact Data